jan henning martens gesellschaftsrecht webp.jpgjulia schaellig gesellschaftsrecht webp.jpg

FGvW advises Gedeon Richter on its investment into German Formycon AG

FGvW advised Hungarian-based Gedeon Richter Nyrt. on its investment into German public listed Formycon AG. By way of a cash capital increase, Gedeon Richter acquired approx. 9 % of the shares in Formycon AG.

Gedeon Richter Nyrt., headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, China, Latin America, and Australia. Having reached a market capitalization of EUR 3.9 billion (USD 4.1 billion) by the end of 2022, Richter's consolidated sales were approximately EUR 2.0 billion (USD 2.1 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women's Healthcare, Central Nervous System, and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women's Healthcare field worldwide. Richter is also active in biosimilar product development.

Formycon (Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY) is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. With FYB201 Formycon already has one biosimilar on the market. Five more are currently in development.

The total inflow of funds to Formycon amounts to EUR 82.84 million and will be used primarily for the further development of Formycon‘s existing biosimilar pipeline, especially FYB206, FYB208 and FYB209.

Advisors to Gedeon Richter: 

Jan Henning Martens, Partner (Lead Partner, M&A/Capital Markets)
Dr. Julia Schällig, Senior Associate (M&A)


1:1. This is how we work together. You decide upon a competent partner; he/she will then remain your point of contact. > more